{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:22:02Z","timestamp":1707524522484},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,28]]},"DOI":"10.7759\/cureus.24556","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T14:58:29Z","timestamp":1651157909000},"source":"Crossref","is-referenced-by-count":2,"title":["Vandetanib-Induced Hyponatremia and Torsades De Pointes: A Case Report"],"prefix":"10.7759","author":[{"given":"Shoaib","family":"Ashraf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niel","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhilasha","family":"Jyala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J","family":"Vittorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause DS","year":"2005","unstructured":"Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005, 353:172-87. 10.1056\/NEJMra044389","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1021\/jm011022e","article-title":"Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors","volume":"45","author":"Hennequin LF","year":"2002","unstructured":"Hennequin LF, Stokes ES, Thomas AP, et al.. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem. 2002, 45:1300-12. 10.1021\/jm011022e","journal-title":"J Med Chem"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann JT","year":"2009","unstructured":"Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009, 10:470-81. 10.2174\/138920009788897975","journal-title":"Curr Drug Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini A","year":"2010","unstructured":"Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010, 102:14-25. 10.1093\/jnci\/djp440","journal-title":"J Natl Cancer Inst"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.11.1363","article-title":"Drug induced QT prolongation and torsades de pointes","volume":"89","author":"Yap YG","year":"2003","unstructured":"Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003, 89:1363-72. 10.1136\/heart.89.11.1363","journal-title":"Heart"},{"key":"ref6","article-title":"Caprelsa (vandetanib) tablets. (2012). Accessed: Oct 15,2020","year":"2020","unstructured":"Caprelsa (vandetanib) tablets. Genzyme Corporation, Cambridge, MA, United States; 2020. http.\/\/www.caprelsa.com\/files\/caprelsa-pi.pdf."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195577","article-title":"Electrophysiological mechanisms of vandetanib-induced cardiotoxicity: comparison of action potentials in rabbit Purkinje fibers and pluripotent stem cell-derived cardiomyocytes","volume":"13","author":"Lee HA","year":"2018","unstructured":"Lee HA, Hyun SA, Byun B, Chae JH, Kim KS. Electrophysiological mechanisms of vandetanib-induced cardiotoxicity: comparison of action potentials in rabbit Purkinje fibers and pluripotent stem cell-derived cardiomyocytes. PLoS One. 2018, 13:e0195577. 10.1371\/journal.pone.0195577","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1831-1","article-title":"Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib","volume":"71","author":"Liu Y","year":"2015","unstructured":"Liu Y, Liu Y, Fan ZW, Li J, Xu GG. Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib. Eur J Clin Pharmacol. 2015, 71:541-7. 10.1007\/s00228-015-1831-1","journal-title":"Eur J Clin Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030353","article-title":"Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis","volume":"7","author":"Zang J","year":"2012","unstructured":"Zang J, Wu S, Tang L, et al.. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS One. 2012, 7:e30353. 10.1371\/journal.pone.0030353","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0025-7125(05)70318-7","article-title":"Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes","volume":"85","author":"Passman R","year":"2001","unstructured":"Passman R, Kadish A. Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. Med Clin North Am. 2001, 85:321-41. 10.1016\/s0025-7125(05)70318-7","journal-title":"Med Clin North Am"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.120295","article-title":"Long QT syndrome: diagnosis and management","volume":"143","author":"Khan IA","year":"2002","unstructured":"Khan IA. Long QT syndrome: diagnosis and management. Am Heart J. 2002, 143:7-14. 10.1067\/mhj.2002.120295","journal-title":"Am Heart J"},{"key":"ref12","article-title":"Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic E14","year":"2005","unstructured":"Guidelines for Industry. Clinical evaluation of QT\/QTc Interval Prolongation And Proarrhythmic Potential For Non-antiarrhythmic E14. U.S. Department of Health and Human Services, Washington D.C., United States; 2005. https:\/\/www.fda.gov\/files\/drugs\/published\/E14-Clinical-Evaluation-of-QT-QTc-Interval-Prolongation-and-Proarrhythmic-P...."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/1715163516641136","article-title":"Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management","volume":"149","author":"Tisdale JE","year":"2016","unstructured":"Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016, 149:139-52. 10.1177\/1715163516641136","journal-title":"Can Pharm J (Ott)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000171","article-title":"Induction therapy for locally advanced, resectable esophagogastric cancer: a phase I trial of vandetanib (ZD6474), paclitaxel, carboplatin, 5-fluorouracil, and radiotherapy followed by resection","volume":"40","author":"Boland PM","year":"2017","unstructured":"Boland PM, Meyer JE, Berger AC, et al.. Induction therapy for locally advanced, resectable esophagogastric cancer: a phase I trial of vandetanib (ZD6474), paclitaxel, carboplatin, 5-fluorouracil, and radiotherapy followed by resection. Am J Clin Oncol. 2017, 40:393-8. 10.1097\/COC.0000000000000171","journal-title":"Am J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells SA Jr","year":"2012","unstructured":"Wells SA Jr, Robinson BG, Gagel RF, et al.. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012, 30:134-41. 10.1200\/JCO.2011.35.5040","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.1709","article-title":"Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)","volume":"30","author":"Lee JS","year":"2012","unstructured":"Lee JS, Hirsh V, Park K, et al.. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol. 2012, 30:1114-21. 10.1200\/JCO.2011.36.1709","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0400","article-title":"Diagnosis and management of hyponatremia in cancer patients","volume":"17","author":"Castillo JJ","year":"2012","unstructured":"Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist. 2012, 17:756-65. 10.1634\/theoncologist.2011-0400","journal-title":"Oncologist"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.08.029","article-title":"Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes","volume":"59","author":"Doshi SM","year":"2012","unstructured":"Doshi SM, Shah P, Lei X, Lahoti A, Salahudeen AK. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis. 2012, 59:222-8. 10.1053\/j.ajkd.2011.08.029","journal-title":"Am J Kidney Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1256668","article-title":"Is hyponatremia a prognostic marker of survival for lung cancer? (Article in German)","volume":"65","author":"Petereit C","year":"2011","unstructured":"Petereit C, Zaba O, Teber I, Groh\u00e9 C. Is hyponatremia a prognostic marker of survival for lung cancer? (Article in German). Pneumologie. 2011, 65:565-71. 10.1055\/s-0030-1256668","journal-title":"Pneumologie"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.krcp.2013.04.008","article-title":"Is VEGF a new therapeutic target for hypertension in chronic kidney disease?","volume":"32","author":"Kim YS","year":"2013","unstructured":"Kim YS. Is VEGF a new therapeutic target for hypertension in chronic kidney disease?. Kidney Res Clin Pract. 2013, 32:49-51. 10.1016\/j.krcp.2013.04.008","journal-title":"Kidney Res Clin Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/66564-vandetanib-induced-hyponatremia-and-torsades-de-pointes-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:25Z","timestamp":1707507565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/66564-vandetanib-induced-hyponatremia-and-torsades-de-pointes-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.24556","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,28]]}}}